Trials / Terminated
TerminatedNCT04042480
A Study of SGN-CD228A in Advanced Solid Tumors
A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Seagen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and how often. Part 2 of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.
Detailed description
This study is designed to evaluate the safety, tolerability, PK, and antitumor activity of SGN-CD228A in select advanced solid tumors. The study will include dose escalation and dose expansion, with multiple disease-specific expansion cohorts.
Conditions
- Cutaneous Melanoma
- Pleural Mesothelioma
- HER2 Negative Breast Neoplasms
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGN-CD228A | SGN-CD228A administered into the vein (IV; intravenously) |
Timeline
- Start date
- 2019-09-03
- Primary completion
- 2023-03-09
- Completion
- 2023-03-09
- First posted
- 2019-08-02
- Last updated
- 2023-03-23
Locations
14 sites across 5 countries: United States, France, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04042480. Inclusion in this directory is not an endorsement.